FindTrial
Sign In

18F-FHBG

OTHER2 trials

Sponsors

Jonsson Comprehensive Cancer Center

Conditions

HLA-A*0201 Positive Cells PresentLocally Advanced Malignant NeoplasmNY-ESO-1 PositiveNY-ESO-1 Positive Tumor Cells PresentRecurrent Plasma Cell MyelomaRefractory Plasma Cell MyelomaSarcomaUnresectable Malignant Neoplasm

Phase 1

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer
TerminatedNCT03240861
Jonsson Comprehensive Cancer CenterHLA-A*0201 Positive Cells Present, Locally Advanced Malignant Neoplasm, NY-ESO-1 Positive +2
Start: 2017-07-26End: 2023-10-19Updated: 2023-11-01
TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma
WithdrawnNCT03506802
Jonsson Comprehensive Cancer CenterHLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Plasma Cell Myeloma +1
Start: 2018-07-10End: 2019-06-25Updated: 2020-07-24

Related Papers

Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny.
2025-07-01
Abstract 914: Preinfusion polyfunctional profiles and cytokine secretion activity of transgenic TCR-T cells, and serum cytokine profiles, are associated with clinical outcomes in sarcoma and melanoma
Cancer Research2023-04-04